Navigation Links
Alexza to Announce 2010 First Quarter Financial Results on Monday, May 10, 2010
Date:4/29/2010

-0894.  International callers may access the live call by dialing 617-213-4860.  The reference number to enter the call is 21092987.

The replay of the conference call may be accessed via the Internet, at www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers.  The reference number for the replay of the call is 17989632.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.  

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, submitted a New Drug Application submission in December 2009, and has a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010.  In February 2010, Alexza established a partnership with Biovail Labor
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
2. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
3. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
4. Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010
5. Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA
6. Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
7. Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
8. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
9. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Diplomat, the nation,s largest ... David Dreyer to the Board of Directors on ... and will also serve as chair of the Audit ... years of accounting, financial, compliance and operating experience in ... has served as chief financial officer, chief operating officer ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Alere Inc. ... rapid diagnostics, issued the following statement today in support ... Antibiotic-Resistant Bacteria. "As the global leader in ... for establishing a national strategy to address the serious ... to work with the Administration on initiatives to promote ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
... Trial Showed REMICADE Therapy is More Likely to Induce ... ... Oct. 6 Data presented for the first time,from the Phase ... Therapy (SONIC) may provide new insights into,the approach to care of ...
... with ... in Clinical Trials -, PHOENIX, Oct. 6 ... focused on the treatment of,obesity and other central nervous ... (naltrexone SR /,bupropion SR), successfully achieved key objectives (lowered ...
Cached Medicine Technology:New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5
(Date:9/19/2014)... Dartmouth researcher, working with The Melanoma Genetics Consortium, GenoMEL, ... in the Journal of the National Cancer Institute ... melanoma. , "For the first time, we have established ... play a part in the risk of developing melanoma," ... School of Medicine at the University of Leeds (UK). ...
(Date:9/19/2014)... 2014 According to a report from ... blood-thinner Xarelto, named as defendants in several lawsuits filed ... moved the court to dismiss those suits because the ... connection with Philadelphia.* The cases include, for instance, Fontan ... Pa. Comm. Pls., Philadelphia Cty.), which was brought by ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Pregnant women who live in ... low birth weight babies, a new study suggests. Researchers ... and found that expectant mothers who lived in a neighborhood ... 20 percent lower risk of very preterm birth (before 30 ... birth (30 to 36 weeks). Babies born to mothers ...
(Date:9/19/2014)... News) -- The U.S. Food and Drug Administration approved a ... part of a class of once-a-week injectable drugs that help ... "Trulicity is a new treatment option, which can ... control blood sugar levels in the overall management of type ... Office of Drug Evaluation II, said in an agency news ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... North Carolina in Chapel Hill that was published in the ... two genes - C282Y and H63D, which are linked to ... increased risk of developing colon cancer. For the research, the ... which, more than 400 already had colon cancer, and were ...
... at Trinity College, Dublin, Ireland, have found from a ... arterial stiffness after smoking even one cigarette in both ... effects of smoking on large artery properties in 185 ... years. 116 non-smokers// were compared with 41 chronic smokers ...
... have traditionally been treated by removing a disc or placing ... together. Now, an artificial disc which is being studied as ... phase one study that was recently completed compared the prosthesis ... patients// were randomized, with one having a fusion operation for ...
... is being reassessed to find out if it could again ... and leprosy. The drug which is unlicensed in Europe was ... morning// sickness. However, it was banned after mothers who took ... for the Evaluation of Medicinal Products (EMEA) is now considering ...
... among children that were known until now were chickenpox, ... neurologists have found that stroke is also among one ... go unnoticed. A National Hospital's database analysis by Dr. ... California showed that four in 1000 newborns had a ...
... recent health survey across England showed that many do ... cancer and other serious diseases. The survey included nearly// ... trends were revealed by the study. ,The survey ... eating and household income. Almost 40% of women in ...
Cached Medicine News:Health News:Artificial discs available as replacements for damaged discs 2Health News:Stroke also in list of common childhood ailments 2
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... are offered as 1-piece or modular, in ... instruments may be customized with handles of ... insulation and flush ports. Many standard patterns ... may affect delivery times. , Please ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
Medicine Products: